BDR Pharma Acquires Controlling Stake in Acme Formulation's Oral Solids Business
BDR Pharma is acquiring a controlling stake in Acme Formulation's oral solid formulations business from existing shareholders, including private equity firm PAG. The deal aims to enhance BDR's contract development and manufacturing platform by adding capabilities in thyroid, women's healthcare, and general medicines. The acquisition supports BDR's growth strategy in oncology, critical care, and international markets, with plans to leverage manufacturing capacity and expand its global presence. PAG will exit as majority owner, while Acme's founder retains a minority stake.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (67/100). Lens Score 45/100.
Outlets measured: thehindu, economictimes, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 9 Nov, 02:29 pm. Other outlets followed.